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Abstract
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in Western countries.
Numerous risk factors have been reported but the evidence and strength of association is variable. We aimed to
identify those risk factors with strong levels of evidence which could be easily assessed by physicians or
ophthalmologists to implement preventive interventions or address current behaviours.
Methods: A systematic review identified 18 prospective and cross-sectional studies and 6 case control studies
involving 113,780 persons with 17,236 cases of late AMD that included an estimate of the association between late
AMD and at least one of 16 pre-selected risk factors. Fixed-effects meta-analyses were conducted for each factor to
combine odds ratio (OR) and/or relative risk (RR) outcomes across studies by study design. Overall raw point
estimates of each risk factor and associated 95% confidence intervals (CI) were calculated.
Results: Increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD showed
strong and consistent associations with late AMD. Risk factors with moderate and consistent associations were
higher body mass index, history of cardiovascular disease, hypertension, and higher plasma fibrinogen. Risk factors
with weaker and inconsistent associations were gender, ethnicity, diabetes, iris colour, history of cerebrovascular
disease, and serum total and HDL cholesterol and triglyceride levels.
Conclusions: Smoking, previous cataract surgery and a family history of AMD are consistent risk factors for AMD.
Cardiovascular risk factors are also associated with AMD. Knowledge of these risk factors that may be easily
assessed by physicians and general ophthalmologists may assist in identification and appropriate referral of persons
at risk of AMD.
Background
Age-related macular degeneration (AMD) is the leading
cause of blindness among people aged 55 years and
older in the U.S and other Western countries [1-3]. Late
stage AMD includes two morphological sub-types: neo-
vascular AMD and geographic atrophy [4,5]. Population
studies indicate that neovascular AMD accounts for two
thirds of late AMD cases, and 90% of blindness from
AMD [6]. Left untreated, neovascular AMD results
in severe visual impairment with an average loss of
around 4 lines of visual acuity within 2 years of disease
onset [7]. Patients with geographic atrophy also develop
visual loss although this tends to be more gradual.
With the introduction of new and effective treatments
for neovascular AMD, there is a strong rationale for
early identification of persons at highest risk of progres-
sion to the late stages as timely treatment given at the
onset of neovascular AMD will lead to better visual out-
comes [8-11]. In this regard, a number of major risk fac-
tors for AMD have been identified, including genetic
(e.g., complement factor H polymorphisms), demo-
graphic (e.g., ethnicity), nutritional (e.g., antioxidant
vitamins, dietary fats or fish), lifestyle (e.g., smoking),
medical (e.g., cardiovascular risk factors), environmental
(e.g., sun exposure), and ocular factors [12-16].
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However, the evidence and strength of association
remain variable in the literature. Furthermore, a number
of these risk factors (e.g., diet and genetic factors) are
not easily measured in routine clinical practice [17-21].
While ocular clinical signs such as drusen and pigmen-
tary irregularities are important markers for progression
to late AMD [22], the skills required for an appropriate
retinal evaluation to be performed followed by the inter-
pretation of the severity of the signs to make a meaning-
ful judgement of risk observed are limited to those with
retinal specialist knowledge. The impending explosion
in immunomodulatory pharmacotherapies which are in
currently in early phase clinical trials constitute another
important reason for non-specialist clinicians and gen-
eral ophthalmologists to be able to refer persons at very
high risk of development of late AMD. Therefore it was
our view that more precise estimates of risk for factors
that could be assessed through routine history taking
would be of value for appropriate counselling and
referral.
Methods
Selection of Risk factors
We performed a systematic review and meta-analysis of
a selection of risk factors for late AMD (neovascular
AMD and geographic atrophy). Initially, we scrutinized
in detail the literature on late AMD to identify all possi-
ble risk factors. The initial search yielded 73 possible
risk factors (Table 1). Following review by an expert
panel (UC, AF, PM, TYW), 16 factors that were consid-
ered to be readily measured in nonspecialist settings
were selected for the full systematic review. We did not
address ocular or genetic risk factors as these require
either specialist skills to conduct the retinal examination
or access to laboratory resources and genetic expertise.
We also excluded nutrition as an estimation of the
nutrition status through dietary questionnaires is also a
specialised field [23].
Data Sources
Searches were conducted in Medline and Cochrane
databases using these terms: macular degeneration OR
age-related macular degeneration OR age-related macu-
lopathy AND gender OR age OR race OR ethnicity OR
iris colour OR diabetes OR cardiovascular OR cerebro-
vascular OR hypertension OR smoking OR cataract sur-
gery OR family history OR body mass index OR
cholesterol OR fibrinogen OR C-reactive protein OR
triglyceride.
Studies and Participants
Prospective cohort, case-control, or cross-sectional stu-
dies, were included if they incorporated an estimate of
Table 1 Potential 73 Risk Factors for Late Age-related
macular degeneration, Identified in the Initial Review
• Ocular factors (n = 15)
• Nuclear opacity
• Cortical opacity
• Pterygium
• Lens opacity
• Horizontal cup-to-disc ratio
• Fellow eye
• Iris color*†
• Eye disease*
• Cataract/Cataract surgery*†
• Arcus cornea
• Arterioar-to-venular ratio
• Frekling
• Spherical equivalents
• Eye glasses for distance vision
• Family history of AMD†
• Cardiovascular factors (n = 7)
• Atherosclerosis
• History of CVD and cerebrovascular disease*†
• Serum Total Cholesterol level† and Serum HDL Cholesterol level†
• Hypertension*†
• Plasma antioxidants
• Other medical conditions or marker (n = 8)
• Biochemical variables* including serum albumin, C-Reactive
Protein,*† plasma fibrinogen,† and serum triglyceride†)
• Bone mineral density
• Diabetes*†
• Arthritis
• Menopause
• Diet (n = 11)
• Dietary intake
• Fat*
• Animal fat*
• Vegetable fat*
• Linoleic acid
• ∞-3 fatty acids EPA/DHA
• Antioxidants*
• Saturated fat
• Monounsaturated fat
• Polyunsaturated fat
• Trans-unsaturated fat
• Medications (n = 9)
• Birth control use
• Diuretics use
• Antacid use
• Antihypertensive medication use
• Anti-inflammatory drug use
• Hydrochlorothiazide use
• Hormone replacement therapy
• Hormones (women)
• Hypnotics/sedative
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association [odds ratio (OR) or relative risk (RR)]
between late AMD and at least one of the 16 risk fac-
tors. Non-English language articles were not included
because, after a preliminary assessment, we did not
identify any that fitted our inclusion criteria. Abstracts
and unpublished studies were also not included.
For articles that passed initial screen, additional
criteria were applied for inclusion in the meta-analysis:
1) estimates for association with neovascular AMD and
geographic atrophy were excluded when concomitantly
presented as late AMD to avoid double counting; 2) for
three epidemiological studies that examined the risk of
late AMD (i.e., Beaver Dam [24-26], Blue Mountains
[24-26], and Rotterdam [25,26]) both the original esti-
mates and pooled estimates of the three studies exist.
Therefore, to avoid double counting of these studies,
only the pooled estimate was retained. We did not
include studies that reported only the unadjusted results
(i.e., crude ORs). All studies included adjusted for age;
when studies reported more than one adjusted estimate,
the multivariate adjusted estimate was selected (i.e., if a
study reported either age adjusted or age, gender and
smoking adjusted results, the latter was chosen).
Outcome Measures
The primary outcome measure was late AMD, or each
type of late AMD if the overall results for late AMD
were not presented.
Study Selection
Searches were completed by 28 February 2007 and
yielded 295 references. The abstracts of these articles
were independently reviewed by two researchers (LP
and CE) and relevant data (e.g., study design, risk factor,
type of AMD) was recorded on a study-specific abstrac-
tion form. Full-text articles were then obtained based on
the initial screening of abstracts and the data extraction
form was completed. Any disagreements between the
two reviewers in the abstract review or following selec-
tion of articles for full text review were resolved by dis-
cussion. The bibliographies of the full text articles that
were reviewed were searched for relevant references.
In all, 128 unduplicated references were initially iden-
tified as being of potential relevance (the search was
repeated in November 2008 and seven additional articles
published in 2008 were included [27-32]), with 12 addi-
tional articles retrieved from the reference lists. From
the total of 147 articles, 70 fulfilled all eligibility criteria
and were selected for meta-analysis. One study was
excluded since the outcome was determined by clinical
criteria rather than retinal photography. In addition, 24
articles were excluded since authors reported progression
for early AMD as well as late AMD. In the final pool, 45
articles were retained for the meta-analyses including arti-
cles with results from 18 prospective studies [24,26,33-49],
and cross-sectional studies [12,25,28,30,31,50-63], and 8
case control studies (Figure 1) [50,64-70].
Data Synthesis
We used Comprehensive Meta-Analysis software version
2 for all meta-analyses. An overall meta-analysis was per-
formed for each risk factor if there were two or more
risk estimates irrespective of study design. In addition,
since the study design could influence the risk estimate,
meta-analyses were performed for each major type of
study within each risk factor. We conducted fixed-effects
and random-effects meta-analyses to combine these out-
comes across included studies by study design, estimating
overall raw point estimates of each risk factor and their
associated 95% confidence intervals (CI). The selection of
fixed-effects vs. random-effects models was based on the
reported I-squared value and associated p-value. If the p-
value was < 0.10 then random-effects was chosen, other-
wise fixed-effects was selected, except when there was
clear heterogeneity based on individual study results and
Table 1 Potential 73 Risk Factors for Late Age-related
macular degeneration, Identified in the Initial Review
(Continued)
• Life style (n = 3)
• Smoking*†
• Alcohol consumption
• Physical activity level
• Light and other exposures (n = 3)
• Place of birth
• Solar radiation/outdoor exposure*
• Chemical exposure
• Genetics (n = 9)
• fibulin 5
• CST3
• CX3CR
• TLR4
• VEGF
• LRP6
• MMP9
• HLA family of genes
• CFH
• Demographics (n = 8)
• Gender*†
• Age*†
• Race/ethnicity*†
• Education*
• Weight/Body mass index*†
• Waist circumference
• Height
• Marital status
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in these instances the more conservative random-effects
was selected. Forest plots were used to graphically pre-
sent the significant findings. Funnel plots were produced
to explore the potential for publication bias.
Results
In total, data from 18 prospective, cross-sectional studies
and 8 case control studies [12,24-26,28,30,31,
33-47,49-54,57-73] were included in the final analysis,
contributing a sample of some 94,058 patients (ranging
from 261 to 22,071) including 3,178 (ranging from 8 to
776) late AMD cases. Table 2 summarizes the characteris-
tics of the 18 prospective and cross-sectional studies from
which estimates were included in the meta-analysis. Fun-
nel plots were reviewed and no evidence of publication
bias was observed.
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Figure 1 Study selection process.
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The findings for each risk factor except age are sum-
marized in Table 3 and discussed separately in the fol-
lowing sections.
Age
All studies found a strong association with increasing
age (Table 4 and Figure 2) [31,74].
Gender
Two estimates from two case control studies [64,65],
two estimates from cross-sectional studies [25,30],
and two prospective studies [27,75] contributed to this
meta-analysis. Findings from this analysis suggest
that there is no significant association between female
gender and late AMD. In the case control studies,
the overall OR for female gender was 1.00 (95%
CI 0.83 - 1.21), in the cross-sectional studies, it
was 1.06 (95% CI 0.78 - 1.44) (Figure 3). In the
prospective studies, it was 1.01 (95% CI 0.89 - 1.16).
Since the authors had not provided the confidence
intervals, one study could not be included in the
model [49].
Table 2 Summary of characteristics of the 18 prospective and cross sectional studies
STUDY NAME LOCATION DATE
OF
STUDY
POPULATION NUMBER OF
LATE AMD
SUBJECTS
AGE
RANGE
%
MALE
METHOD OF
FUNDUS
CAPTURE
METHOD OF
CLASSIFICATION
AREDS [64] USA 1992-
1998
4,519 776 60-80 NA Retinal photo WARMGS
Baltimore Eye Study*[91] USA 1985-
1988
4,396 48 40+ NA Retinal photo International AMD
Barbados Eye Study*[42] Barbados 1988-
1992
2,374 12 40-84 43 Retinal photo Described in paper
Beaver Dam Eye Study
[24-26,39,47,57,92]
USA 1988-
1990
4,926 72 43-86 44 Retinal photo WARMGS
Blue Mountains Eye Study*
[24-26,35,43,46]
Australia 1992-
1994
3,654 65 49+ 43 Retinal photo WARMGS
Cardiovascular Health Study
[40]
USA 1989-
1990
5,201 35 65+ 60 Retinal photo WARMGS
Copenhagen City Study*
[33,49]
Denmark 1986-
1988,
2000-
2002
946 112 60-80 49 Retinal photo Described in paper
European Study of Eye
Disease (EUREYE)[12]
Europe 2000-
2003
4,752 158 Aged
65+
45 Retinal photo International AMD
Funagata Study[30] Japan 2000-
2002
3,676 8 35+ 51 Retinal photo WARMGS
Los Angeles Latino Eye
Study (LALES) *[53,54,61]
USA 1997-
2002
5,875 25 40+ 42 Retinal photo WARMGS
Multi-ethnic Study of
Atherosclerosis (MESA)[41,59]
USA 2002-
2004
6,176 27 45-85 48 Retinal photo WARMGS
NHANES III*[58] USA 1998-
1994
8,270 54 40+ 47 Retinal photo WARMGS
PHS[34,44] USA 1982-
1989
22,071 64 40+ 100 Retinal photo WARMGS
Progression of Age-related
Macular Degeneration Study
(PARMDS)[45]
USA 1989-
1998
261 NA 60+ NA Retinal photo Modification of the Age-
Related Eye Disease Study
Grading system
Pathologie Occulaires Liees a
l’age (POLA) *[51,52]
France 2002,
2006
2,183 41 60+ 43 Retinal photo Fundus photo
Proyecto VER*[93] USA 1997-
1999
2,780 15 50+ 39 Retinal photo WARMGS
Rotterdam Study*
[25,26,36,62,94]
Netherlands 1990-
1993
6,251 104 55+ 40 Retinal photo WARMGS
Singapore Malay Eye Study
(SiMES)[28,31]
Singapore 1992 3,280 23 40-80 52 Retinal photo WARMGS
WARMGS: Wisconsin Age-Related Maculopathy Grading System; * Studies included in the meta-analyses
* From article referenced
Note: Case control studies were not included in this table
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Race/ethnicity
One case control study (AREDS) [64], two cross sec-
tional studies (NHANES III and LALES) [53,58] and
two prospective studies (MESA, CHS) [41,76] contribu-
ted to this analysis. All studies were based in the US
population. In the MESA Study [41], there were no sig-
nificant differences between whites (European origin),
Asians (i.e. predominantly Chinese ancestry), Blacks
(African Americans) or Hispanics in late AMD preva-
lence. In the NHANES III [58], there were no significant
differences between Non-Hispanic White, Non-Hispanic
Black (OR 0.34, 95%CI 0.10 - 1.18) and Mexican Ameri-
cans (OR 0.25, 95% CI 0.07 - 0.90). In the LALES [53],
individuals of Native American ancestry were nearly 15
times more likely to have geographic atrophy (95% CI
1.8 - 12.6) than Latinos. The OR was 0.91 (0.49 - 1.69)
in prospective cohort studies and 1.09 (0.09 - 13.56) in
cross-sectional studies for whites versus other races/eth-
nicities (Figure 4). An additional study, the Baltimore
Eye Study [77], was identified; however, the use of
differing nomenclatures in the Baltimore Eye Study to
identify racial types (e.g., African American, Chinese,
Mexican American) prevented its inclusion in the meta-
analysis.
Family history
Two case control studies were included in the meta-
analysis [68,69]. Findings from the meta-analysis show
an insignificant association between family history and
late AMD (OR 6.18; 95% CI 1.94 - 6.61). This was sup-
ported by findings from a cross-sectional study (OR
3.95. 95% CI 1.35 - 11.54) (Figure 5) [60].
Cataract surgery
Estimates from three prospective cohort studies
(i.e., Copenhagen, Blue Mountains, and Beaver Dam)
[24,27,35,38] at five-years and ten-years, and from five
cross-sectional studies (Salisbury Eye Evaluation, Proyecto
VER, Baltimore Eye Survey, and Blue Mountains) [63,78],
were analyzed. Only two case control studies [50,66] were
Table 3 Summary Results from the Meta-analysis
RISK FACTOR PROSPECTIVE CROSS-SECTIONAL CASE CONTROL
n Overall estimate n Overall estimate n Overall estimate
Gender (female) 2 1.01 (0.89 - 1.16) 2 1.06 (0.78 - 1.44) 2 1.00 (0.83 - 1.21)
Race (white vs. other) 3 0.91 (0.49 - 1.69) 3 1.09 (0.09 - 13.56)* 1 4.2 (2.23 - 8.00)
Family History* 0 1 3.95 (1.35 - 11.54) 2 6.18 (0.98 - 38.90)*
Cataract surgery* 4 3.05 (2.05 - 4.55) 2 1.59 (1.08 - 2.34) 3 1.54 (1.24 - 1.91)
Iris colour* 5 0.98 (0.72 - 1.32) 4 0.88 (0.65 - 1.17) 2 0.60 (0.12 - 2.98)*
Body Mass Index* 9 1.28 (0.98 - 1.67)* 10 1.21 (0.97 - 1.53) 2 1.52 (1.15 - 2.00)
Smoking* 5 1.86 (1.27 - 2.73) 7 3.58 (2.68 - 4.79) 6 1.78 (1.52 - 2.09)
Hypertension* 4 1.02 (0.77 - 1.35) 6 1.15 (0.88 - 1.51) 3 1.48 (1.22 - 1.78)
Diabetes* 3 1.66 (1.05 - 2.63) 3 1.09 (0.61 - 1.92) 1 0.55 (0.06 - 4.87)
Cardiovascular Disease* 7 1.22 (0.92 - 1.63) 9 1.12 (0.86 - 1.47) 6 2.20 (1.49 - 3.26)*
Cerebrovascular Diseases 2 1.54 (0.82 - 2.90) 5 1.10 (0.69 - 1.75) 0
Serum Cholesterol (Total) 4 0.99 (0.95 - 1.03) 5 0.94 (0.84 - 1.04) 1 4.66 (1.35 - 16.11)
Serum Cholesterol (HDL) 3 1.00 (0.97 - 1.02) 5 1.06 (0.80 - 1.39) 1 3.35 (0.92 - 12.23)
Serum Triglycerides 2 1.00 (0.77 - 1.30) 3 1.08 (0.89 - 1.30) 1 0.90 (0.25 - 3.24)
Plasma Fibrinogen* 1 1.03 (0.81 - 1.32) 3 1.45 (1.22 - 1.73) 0
n = number of estimates entered in the models; *Figure is displayed
* Estimates from random effects models. All other estimates are fixed effects.
Table 4 Prevalence of late AMD by age (Adapted from Varma et al68 and Kawasaki et al29)
Age Los Angeles Baltimore Blue Mountains Beaver Dam Baltimore Barbados SiMES
Group Latino White White White Black Black Asian
(yrs) [% (CI)] [% (CI)] [% (CI)] [% (CI)] [% (CI)] [% (CI)] [%]
40 – 49 0.0 0.0 0.0 0.4 (0.0 – 0.8) 0
50 – 59 0.2 (0.0 – 0.4) 0.5 (0.0 – 1.1) 0.0 0.2 (0.0 – 0.4) 0.4 (0.0 – 0.8) 0.7 (0.2 – 1.2) 0.21
60 – 69 0.3 (0.0 – 0.6) 0.7 (0.1 – 1.3) 0.5 (0.1 – 0.8) 0.8 (0.3 – 1.3) 0.4 (0.0 – 1.0) 0.4 (0.0 – 0.8) 0.39
70 – 79 1.5 (0.5 – 2.5) 2.9 (1.5 – 4.4) 2.6 (1.6 – 3.6) 3.7 (2.5 – 4.9) 0.0 1.0 (0.0 – 2.0) 2.49
≥ 80 8.5 (3.5 – 13.5) 7.0 (2.0 – 12.0) 12.0 (8.7 – 15.4) 9.5 (6.2 – 12.8) 0.0 0.0
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found. Analysis of the prospective cohort studies showed
that previous cataract surgery is a strong risk factor for
neovascular AMD (RR 3.05; CI 2.05 - 4.55). This finding is
supported by the results of the meta-analysis of the cross-
sectional studies (OR = 1.59; CI 1.08 - 2.34) (Figure 6).
Smoking
Estimates were reported from six prospective cohort
studies [26,33,34,42,79], five case control studies
[64,65,67,68,70] and five cross-sectional studies
[12,25,28,30,51] contributed to the meta-analysis. Signifi-
cant increases in AMD risk were seen in all the meta-
analyses for current versus never smokers. The OR for
case control studies was 1.78 (95% CI 1.52 - 2.09), and
that from cross-sectional studies was 3.58 (95% CI 2.68
- 4.79). The RR obtained through analysis of prospective
cohort studies was 1.86 (95% CI 1.27 - 2.73) (Figure 7).
Iris colour
Data from three prospective cohort studies [26,27,47],
from two control studies [65,68] and a pooled estimate
from a cross sectional study [25] were used in the meta-
analysis. Two studies were not used because the authors
had not provided the confidence interval of the estimate
[37,64], or because the data had already been considered
within a pooled analysis [58]. The meta-analysis of the
prospective cohort and cross-sectional studies suggests
that darker iris pigmentation (brown vs. blue eyes) is
protective, but the overall results were not significant
(OR 0.88; 95% CI 0.65 - 1.17 cross-sectional studies and
RR 0.98; 95% CI: 0.72 - 1.32 for prospective studies).
The case control results support this finding (0.60; 95%
CI 0.12 - 2.98) (Figure 8).
Body Mass Index (BMI)
Seven prospective cohort studies (Copenhagen, CHS,
PHS, PARMDS, Beaver Dam, Rotterdam, Blue Moun-
tains) [26,33,44-46,80] and six cross-sectional studies
(POLA, Beaver Dam, Rotterdam, Blue Mountains,
LALES, SiMES) [25,28,52,54] contributed to the meta-
analysis. Analysis of the prospective studies showed an
adverse effect of being overweight/obese and the risk of
late AMD (RR 1.28; 95% CI 0.98 - 1.67). Cross-sectional
study findings were in the same direction but did not
reach statistical significance (OR 1.21; 95% CI 0.97 -
1.53). However, the two case control studies [64,67] did
achieve statistical significance (OR 1.52; 95% 1.15 - 2.00)
(Figure 9).
Hypertension
Estimates from five prospective cohort studies
[26,27,42,46], three cases control studies [64,65,67], and
from seven cross-sectional studies [25,28,30,52,54]
0
2
4
6
8
10
12
14
40-49 50-59 60-69 70-79 80
Kawasaki Baltimore (White) Beaver Dam (White)
Barbados (Black) Blue Mountains (White) Baltimore (Black)
LALES (Latino)
Figure 2 Prevalence of late AMD by age (adapted from Varma
et al [61] and Kawasaki et al [19]).
Group by
Subgroup within study
Study name Subgroup within studyComparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CC AREDS, GA-AMD CC Male 1.350 0.882 2.066
CC AREDS, NV-AMD CC Male 0.950 0.767 1.176
CC Blumenkranz 1986, NV-AMD CC Male 0.457 0.122 1.719
CC 1.003 0.830 1.212
CS Smith 2001, GA-AMD CS Male 1.450 0.876 2.400
CS Smith 2001, NV-AMD CS Male 0.950 0.640 1.410
CS Kawasaki 2008, Late AMD CS Male 0.280 0.058 1.353
CS 1.059 0.781 1.437
PC Buch 2005, Late AMD PC Male 1.250 0.732 2.135
PC Van Leeuwen 2003, Late AMD PC Male 1.000 0.870 1.150
PC 1.014 0.886 1.161
0.01 0.1 1 10 100
Gender
Figure 3 Pooled odds ratio for late AMD by gender (female vs.
male).
Group by
Subgroup 
within study
Study name
Subgroup 
within study Comparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CC AREDS, NV-AMD CC White 4.220 2.229 7.988
CC 4.220 2.229 7.988
PC Klein 2006, Late AMD a PC Black 0.520 0.169 1.595
PC Klein 2006, Late AMD b PC Chinese 1.910 0.750 4.867
PC Klein 2006, Late AMD PC Hispanics 0.480 0.138 1.673
PC 0.907 0.487 1.690
Race/Ethnicity
Fraser-Bell 2005, GA-AMD CS Native american 16.440 3.935 68.685
Klein 1999, Late AMD a CS Mexican Americans 0.250 0.070 0.896
Klein 1999, Late AMD b CS Non-hispanic blacks 0.340 0.099 1.168
1.094 0.088 13.560
0.01 0.1 1 10 100
CS
CS
CS
Figure 4 Pooled odds ratio for late AMD and by race/ethnicity
(whites vs. other races/ethnicities).
Group by
Subgroup 
within study
Study name
Subgroup 
within study Comparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
0.01 0.1 1 10 100
Family History
CC Hyman 1983, Late AMD CC Family history
CC Klaver 1998, Late AMD CC Family history
CC
CS Smith 1998, Late AMD CS Family history 3.950 1.352 11.539
CS 3.950 1.352 11.539
2.900 1.514 5.553
19.800 3.106 126.232
6.180 0.982 38.896
Figure 5 Pooled odds ratio for late AMD by family history
(presence or absence).
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contributed to this analysis. None of the analyses
showed statistically significant associations (prospective
cohort RR 1.02; 95% CI 0.77 - 1.35; cross-sectional stu-
dies OR 1.15; 95% CI: 0.88 - 1.51). The three case con-
trol studies did identify a significant association between
presence of hypertension and late AMD (OR 1.48; 95%
CI 1.22 - 1.78) (Figure 10).
Diabetes
Estimates from four prospective cohort studies
[24,42,46] and two cross-sectional estimates [52,54,60]
contributed to the meta-analysis. Based on the data
from the prospective cohort studies, the presence of
diabetes was associated with an increased risk of late
AMD (RR 1.66; 95% CI 1.05 - 2.63). In the cross-sec-
tional estimates that used data from two studies, asso-
ciations were nonsignificant (OR 1.09; 95% CI 0.61 -
1.92). Only one case control study [65] showed non-
significant association with diabetes (OR 0.55; 95% CI
0.06 - 4.87) (Figure 11).
History of Cardiovascular Disease
Five prospective cohort studies (including pooled esti-
mates) [26,33,42,46] four case control studies [65-68]
and seven cross-sectional studies [28,52,54,58] (including
pooled estimates [25]) contributed to the meta-analysis
of history of cardiovascular disease (self or medical
report) and late AMD. As previously mentioned, some
estimates [49,81] were not retained in the analysis. No
significant association was found in the prospective
cohort and the cross-sectional studies (RR 1.22, 95% CI
0.92 - 1.63 and OR 1.12; 95% CI 0.86 - 1.47). A signifi-
cant association was observed in the case control stu-
dies, with around double the odds of late AMD in
individuals with cardiovascular disease (OR 2.20; 95% CI
1.48 - 3.26) (Figure 12).
History of Cerebrovascular Diseases
Three prospective cohort studies [26,46] and six cross-
sectional studies [25,28,52,54] were included in the
meta-analysis of history of cerebrovascular diseases and
late AMD (Figure 13). No significant associations were
found (RR 1.54; 95% CI 0.82 - 2.90 and OR 1.10, 95%CI
0.69 - 1.75 for the prospective and the cross-sectional
studies, respectively).
Group by
Subgroup within study
Study name Subgroup within study Comparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CC Chaine 1998, GA-AMD CC Previous surgery 1.780 1.227 2.583
CC Chaine 1998, NV-AMD CC Previous surgery 1.440 1.094 1.896
CC Baatz 2008, NV-AMD CC Cataract surgery 1.300 0.522 3.240
CC 1.537 1.239 1.906
CS Freeman 2003, Late AMD CS Cataract surgery 1.700 1.106 2.614
CS Wang 1999, Late AMD CS Past cataract 1.200 0.498 2.890
CS 1.589 1.080 2.339
PC Buch 2005, Late AMD PC Cataract extraction 1.600 0.800 3.200
PC Cugati 2006, Late AMD PC Nonphakic 3.310 1.110 9.870
PC Klein 2002, Late AMD PC Cataract surgery 3.810 1.889 7.685
PC Wang 2003, Late AMD PC Nonphakic 5.700 2.394 13.569
PC 3.054 2.049 4.552
0.01 0.1 1 10 100
Cataract Surgery
Figure 6 Pooled odds ratio for late AMD by history of previous
cataract surgery.
Group by
Subgroup within study
Study name Subgroup within study Comparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CC AREDS group, NV-AMD CC Current smoker1.910 1.568 2.327
CC AREDS group, GA-AMD CC Current smoker1.610 1.066 2.433
CC Blumenkranz 1986, NV-AMD CC Current smoker1.250 0.328 4.762
CC Hyman 1983, Late AMD CC Current smoker1.200 0.781 1.843
CC Tamakoshi 1997, NV-AMD CC Current smoker2.970 0.999 8.830
CC Hogg, NV-AMD CC Current smoker3.710 1.247 11.036
CC 1.777 1.515 2.085
CS Chakravarthy 2007, GA-AMD CS Current smoker4.810 2.084 11.102
CS Chakravarthy 2007, NV-AMD CS Current smoker2.550 1.352 4.811
CS Delcourt 1998, Late AMD CS Current smoker3.500 1.002 12.225
CS Smith 2001, GA-AMD CS Current smoker2.540 1.249 5.166
CS Smith 2001, NV-AMD CS Current smoker4.550 2.743 7.548
CS Cakett 2008, Late AMD CS Current smoker3.790 1.402 10.245
CS Kawasaki 2008, Late AMD CS Current smoker5.030 0.997 25.385
CS 3.582 2.679 4.791
PC Buch 2005, Late AMD PC Current smoker1.600 0.629 4.072
PC Christen 1996, NV-AMD PC Current smoker1.950 0.893 4.256
PC Klein 2002, NV-AMD PC Current smoker0.850 0.284 2.545
PC Leske 2006, Late AMD PC Current smoker2.300 0.507 10.439
PC Tomany 2004, Late AMD PC Current smoker2.350 1.297 4.259
PC 1.862 1.272 2.726
0.01 0.1 1 10 100
Smoking
 
Figure 7 Pooled odds ratio for late AMD by smoking status
(current vs. never).
Group by
Subgroup 
within study
Study name
Subgroup 
within study Comparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
Iris Color
CC Blumenkranz 1986, NV-AMD CC Brown 1.490 0.439 5.055
CC Hyman 1983, Late AMD CC Brown 0.290 0.150 0.560
CC 0.604 0.123 2.979
CS Smith 2001, GA-AMD a CS Hazel/green 0.710 0.329 1.534
CS Smith 2001, NV-AMD a CS Hazel/green 0.790 0.446 1.398
CS Smith 2001, GA-AMD b CS Tan/brown 0.640 0.319 1.285
CS Smith 2001, NV-AMD b CS Tan/brown 1.150 0.730 1.811
CS 0.876 0.654 1.174
PC Buch 2005, Late AMD a PC Gray/green 0.900 0.413 1.962
PC Buch 2005, Late AMD b PC Brown 1.300 0.531 3.184
PC Tomany 2003, Late AMD a PC Green 0.960 0.511 1.804
PC Tomany 2003, Late AMD b PC Brown 0.720 0.369 1.405
PC Tomany 2004, Late AMD PC Brown 1.130 0.659 1.937
PC 0.977 0.723 1.319
Figure 8 Pooled odds ratio for late AMD by iris color (brown
vs. blue eyes).
Group by
Subgroup 
within study
Study name Subgroup 
within study
Comparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
Body Mass Index
PC Buch 2005, Late AMD PC BMI>27 1.300 0.672 2.515
PC Klein 2003, Late AMD PC BMI>30 1.100 0.632 1.915
PC Schaumberg 2001, Late AMD a PC BMI 25-30 0.780 0.452 1.346
PC Schaumberg 2001, Late AMD b PC BMI>30 1.280 0.489 3.351
PC Seddon 2003, Late AMD a PC BMI 25-30 2.320 1.321 4.074
PC Seddon 2003, Late AMD b PC BMI>30 2.350 1.271 4.345
PC Tan 2007, Late AMD a PC Overweight 1.220 0.678 2.195
PC Tan 2007, Late AMD b PC Obese 1.200 0.566 2.544
PC Tomany 2004, Late AMD PC BMI>30 0.870 0.512 1.478
PC 1.278 0.976 1.673
0.01 0.1 1 10 100
CC AREDS group, Late AMD CC BMI >31 1.430 1.075 1.902
CC Hogg, NV-AMD CC BMI 27-30 3.820 1.218 11.985
CC 1.515 1.149 1.997
CS Delcourt 2001, Late AMD a CS BMI 25-30 0.940 0.442 1.999
CS Delcourt 2001, Late AMD b CS BMI >30 2.290 1.001 5.238
CS Smith 2001, GA-AMD a CS BMI 26-30 1.520 0.820 2.818
CS Smith 2001, GA-AMD b CS BMI>30 1.510 0.719 3.172
CS Smith 2001, NV-AMD a CS BMI 26-30 0.940 0.596 1.482
CS Smith 2001, NV-AMD b CS BMI>30 1.190 0.694 2.041
CS Cakett 2008, Late AMD a CS BMI 25-30 0.930 0.349 2.481
CS Cakett 2008, Late AMD b CS BMI>30 1.370 0.408 4.604
CS Fraser-Bell 2008, Late AMD a CS BMI 25-30 1.220 0.362 4.107
CS Fraser-Bell 2008, Late AMD b CS BMI>30 1.280 0.376 4.356
CS 1.214 0.965 1.527
Figure 9 Pooled odds ratio for late AMD by body mass index
(obese vs. non-obese).
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Biological markers
Five prospective cohort studies [26,33,40,46] (including
one pooled estimate), and six cross-sectional studies
[28,30,52] (including one pooled estimate [25]), one case
control [67] of serum total cholesterol and of serum
high-density lipoprotein cholesterol contributed to the
meta-analysis (data not shown). Three studies [49,57,82]
were not included in the meta-analysis. The pooled
odds ratios and relative risks were non-significant for
both serum cholesterol measures.
Neither the two prospective cohort studies [27,46] (RR
1.0; 95% CI 0.77 - 1.30) nor the cross-sectional studies
[28,52,60] (OR 1.08; 95% CI 0.89 - 1.30), found an asso-
ciation between serum triglycerides and late AMD (data
not shown).
A significant increase in risk of late AMD with
increased plasma fibrinogen was observed in two cross-
sectional studies [58-60], (OR 1.45; 95% CI 1.22 - 1.73).
There was only one estimate from a prospective study
[46] and it did not support this finding (OR 1.03; 95%
CI 0.81 - 1.32) of significance in the cross-sectional stu-
dies (Figure 14).
None of the studies which measured C-reactive pro-
tein [36] were eligible for inclusion in our meta-analysis.
Discussion
Identifying patients at high risk of late AMD, particu-
larly neovascular AMD, is important from both public
health and clinical perspectives as this would facilitate
detection of disease before the onset of irreversible
visual loss enabling earlier intervention. Of the 16 risk
factors identified in our systematic review and meta-
analysis, age, current smoking, cataract surgery, and
potentially family history were strongly and consistently
associated with late AMD. All of these are easily
assessed through discussions with patients and do not
entail a lengthy medical history taking or laboratory eva-
luations. Other significant factors with a lower strength
of association (risk estimates generally 1.5 or less) were
BMI, hypertension, a history of cardiovascular disease
and plasma fibrinogen. All of these factors are associated
with cardiovascular disease and are also likely to be
measured and monitored in the primary care setting.
Our meta-analysis confirmed the increased risks of
late AMD associated with advancing age (especially for
the oldest age groups of 80 years and over), current
cigarette smoking, and previous cataract surgery. The
relationship of cataract surgery and late AMD was pre-
viously reported in a pooled analysis of 3 studies in dif-
ferent continents [26]. Although this association could
reflect shared risk factors and the fact that both are dis-
eases that affect the ageing eye, there is concern that
surgery may predispose the operated eye to the
Group by
Subgroup within study
Study name Subgroup within studyComparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CC AREDS group, Late AMD CC Hypertension1.450 1.197 1.756
CC Blumenkranz 1986, Late AMD CC Hypertension0.600 0.089 4.045
CC Hogg, NV-AMD CC Hypertension3.210 1.144 9.009
CC 1.476 1.224 1.780
CS Delcourt 2001, NV-AMD CS Hypertension1.050 0.548 2.012
CS Smith 2001, GA-AMD CS Hypertension0.720 0.391 1.325
CS Smith 2001, NV-AMD CS Hypertension1.480 0.988 2.217
CS Fraser-Bell 2008, Late AMD CS Hypertension1.300 0.577 2.927
CS Cakett 2008, Late AMD CS Hypertension0.870 0.248 3.054
CS Kawasaki 2008, Late AMD CS Hypertension1.060 0.253 4.447
CS 1.154 0.882 1.510
PC Buch 2005, Late AMD PC Hypertension0.980 0.503 1.910
PC Leske 2006, Late AMD PC Hypertension1.500 0.506 4.448
PC Tan 2007, Late AMD PC Hypertension0.920 0.548 1.544
PC Tomany 2004, Late AMD PC Hypertension1.050 0.699 1.577
PC 1.022 0.773 1.351
0.01 0.1 1 10 100
Hypertension
Figure 10 Pooled odds ratio for late AMD by hypertension
(presence or absence).
Group by
Subgroup within study
Study name Subgroup within studyComparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CC Blumenkranz 1986, NV-AMD CC Diabetes 0.550 0.062 4.873
CC 0.550 0.062 4.873
CS Delcourt 2001, Late AMD CS Diabetes 1.220 0.451 3.300
CS Smith 1998, Late AMD CS Diabetes 1.180 0.450 3.093
CS Fraser-Bell 2008, Late AMD CS Diabetes 0.880 0.321 2.410
CS 1.086 0.614 1.921
PC Leske 2006, Late AMD PC Diabetes 2.700 0.999 7.296
PC Tan 2007, Late AMD PC Diabetes 1.920 0.838 4.399
PC Tomany 2004, Late AMD PC Diabetes 1.210 0.620 2.361
PC 1.659 1.046 2.630
0.01 0.1 1 10 100
Diabetes
Figure 11 Pooled odds ratio for late AMD by diabetes
(presence or absence).
Group by
Subgroup 
within study
Study name Subgroup 
within study
Comparison Point (raw) and 95% CIPoint Lower Upper 
(raw) limit limit
CC Blumenkranz, NV-AMD CC Angina 4.000 0.239 67.002
CC Chaine, NV-AMD CC CVD 3.190 1.807 5.631
CC Chaine, GA-AMD CC CVD 1.490 1.031 2.153
CC Hyman, Late AMD a CC CVD History 1.700 1.078 2.682
CC Hyman, Late AMD b CC Angina 1.700 1.085 2.663
CC Hogg, NV-AMD CC CVD History 7.530 2.779 20.403
CC 2.198 1.484 3.255
CS Delcourt, Late AMD CS Any CVD 1.460 0.719 2.965
CS Klein, GA-AMD CS MI 2.020 0.679 6.010
CS Smith 2001, NV-AMD a CS Angina 1.030 0.603 1.759
CS Smith 2001, GA-AMD a CS Angina 0.560 0.220 1.423
CS Smith 2001, NV-AMD b CS Acute MI 0.940 0.520 1.700
CS Smith 2001, GA-AMD b CS Acute MI 0.760 0.327 1.765
CS Cakett, Late AMD CS MI History 1.290 0.371 4.484
CS Fraser-Bell, Late AMD a CS MI History 1.880 0.532 6.639
CS Fraser-Bell, Late AMD b CS Angina 2.720 0.890 8.316
CS 1.121 0.857 1.468
PC Buch, Late AMD a PC Angina 1.100
0.588 2.058
PC Buch, Late AMD b PC CVD 0.600
0.080 4.475
PC Leske, Late AMD PC CVD History
1.200 0.280 5.138
PC Tan 2007, Late AMD a PC Any CVD 1.450
0.804 2.614
PC Tan 2007, Late AMD b PC Angina 1.560
0.821 2.964
PC Tan 2007, Late AMD c PC MI 1.400
0.616 3.181
PC Tomany, Late AMD PC MI History
0.810 0.401 1.635
PC 1.222
0.917 1.629
0.01 0.1 1 10 100
Cardiovascular Disease
Figure 12 Pooled odds ratio for late AMD by cardiovascular
disease (presence or absence).
Group by
Subgroup within study
Study name Subgroup within studyComparison Point (raw) and 95% CI
Point Lower Upper 
(raw) limit limit
CS Delcourt 2001, Late AMD CS Stroke 0.910 0.208 3.981
CS Smith 2001, GA-AMD CS Stroke 0.720 0.260 1.997
CS Smith 2001, NV-AMD CS Stroke 1.070 0.550 2.081
CS Fraser-Bell 2008, Late AMD CS Stroke 2.330 0.712 7.628
CS Cakett 2008, Late AMD CS Stroke 1.230 0.161 9.423
CS 1.101 0.692 1.752
PC Tan 2007, Late AMD PC Stroke 1.980 0.789 4.966
PC Tomany 2004, Late AMD PC Stroke 1.240 0.523 2.938
PC 1.544 0.823 2.896
0.01 0.1 1 10 100
Stroke/Cerebrovascular
Figure 13 Pooled odds ratio for late AMD by cerebrovascular
disease (presence or absence).
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development of neovascular AMD. We further con-
firmed the association with family history of AMD, con-
sistent with the growing recognition of major genes
involved in AMD (e.g., complement factor H and C3,
LOCS 3877, HTRA 1) [21,83-86].
Vascular diseases, including myocardial infarction,
stroke, angina, and hypertension are thought to be
pathogenic factors for the development of late AMD.
Our meta-analysis showed that while the magnitude of
the ORs were inconsistent across studies, the pooled
estimates for case-control studies were statistically sig-
nificant for both cardiovascular disease (OR 2.20; 95%
CI 1.49 - 3.26) and hypertension (OR 1.48, 95% CI 1.22
- 1.78). The association of diabetes and late AMD is
also less consistent, and while prospective studies
showed a significant association, this was not significant
in the cross-sectional or case-control studies. The rela-
tionship between higher BMI and late AMD could be
explained by shared risk factors (e.g., hypertension), or
potential unmeasured confounders (e.g., nutritional fac-
tors). Our analysis also indicated that, based only on US
data, people of European origin were at increased risk
compared to other ethnic groups but at present the evi-
dence for risks associated with other specific ethnic
groups is inadequate. These are areas of future research.
Our study has several limitations. Although we
selected only studies that reported some adjustment for
confounding factors, we could not ascertain the appro-
priateness or completeness of adjustment in the studies.
Second, the data included in some studies may have
been too crude and also subject to measurement error.
For example, a ‘history of cardiovascular disease’ may
encompass a spectrum of conditions, from asympto-
matic angina to myocardial infarction; this was not
often specified. Such potential measurement errors
would likely dilute effects in the meta-analysis. Third,
we did not consider ocular factors (e.g., presence of
large drusen), that have been found to be strong predic-
tors of progression to late AMD, as we felt they could
not be easily ascertained by family physicians. Neither
did we consider dietary factors, such as the consumption
of vegetables rich in carotenoids (lutein and zeaxanthin)
or zinc and antioxidant vitamin supplementation, fish or
omega-3 fatty acids in the diet, or glycemic index,
because the methods for estimating such risk factors in
the setting of primary health care is difficult without
access to specialised personnel and resources [6,87-89].
Fourth, despite strong associations of AMD with genetic
factors, we felt that genetic testing was not readily avail-
able in general clinical practice. Fifth, we included only
English language articles because a preliminary assess-
ment did not identify any non-English language articles
that fitted our inclusion criteria. Nonetheless, many stu-
dies included in this review were from non-white popu-
lations (e.g., Chinese, Malay Asians) and thus, we
believe our results can be generalisable to different
populations in different countries around the world.
Sixth, we only included articles that were identified in
the Medline and Cochrane databases. Expanding the
search to EMBASE may have identified additional arti-
cles; however, given the extensive hand searching of bib-
liographies and the experience of the authors we feel it
is unlikely any relevant articles were missed. Seventh,
the assessment of the quality of the publications was
performed as part of this study to provide supplemen-
tary evidence of the internal and external validity of the
data. However, ultimately, we decided to present
the data based on the type of study design reported in
the publication: cohort, cross sectional and case control.
Large, epidemiological, cohort studies had the advantage
over other study designs in that they removed any tem-
poral or causal ambiguity as the exposure precedes the
disease and if follow-up is not biased selection bias is
less of a problem than in other study designs [90].
Finally, whether the study findings could be used as
prognostic information to refer patients with higher risk
of AMD requires further research. The observed odds
ratios were generally small, and there are limited inter-
ventions to prevent AMD.
Conclusions
Our systematic review and meta-analysis identified four
strong and consistent risk factors for late AMD (increas-
ing age, current smoking, previous cataract surgery and
an AMD family history) and a further four risk factors
showing significant and moderate strength of associa-
tions (high BMI, history of cardiovascular disease,
hypertension and plasma fibrinogen). This study pro-
vides additional information for primary care physicians,
general ophthalmologists and other eye care profes-
sionals to counsel their patients on AMD risk.
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